Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $59.39 USD
Change Today -2.58 / -4.16%
Volume 5.0M
As of 1:11 PM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/20/15 - $70.54
52 Week Low
10/15/14 - $47.55
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BRISTOL-MYERS SQUIBB CO (BMY)

bristol-myers squibb co (BMY) Details

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular. The company’s products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; and Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. Its products also comprise Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia for use in treating patients with moderately to severely active rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. In addition, it is developing Opdivo, a human monoclonal antibody, which is in Phase III trials for non-small cell lung cancer, renal cell cancer, and melanoma; Beclabuvir, a non-nucleoside NS5B inhibitor that is in Phase III development for the treatment of HCV; Elotuzumab, a humanized monoclonal antibody, which is in Phase III trials for the treatment of multiple myeloma; and BMS-663068, an investigational compound that is being studied in HIV-1. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

25,000 Employees
Last Reported Date: 02/13/15
Founded in 1887

bristol-myers squibb co (BMY) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $916.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $910.5K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $875.0K
Executive Vice President and General Counsel
Total Annual Compensation: $849.8K
Compensation as of Fiscal Year 2014.

bristol-myers squibb co (BMY) Key Developments

Bristol-Myers Squibb Pays $14 Million to Settle SEC Charges

Bristol-Myers Squibb announced that it has agreed to pay more than $14 million to the Securities and Exchange Commission (SEC) to settle charges that its joint venture in China made cash payments and provided other benefits to health care providers (HCPs) at state-owned and state-controlled hospitals in exchange for prescription sales. The payment comes as SEC found B-MS violated the Foreign Corrupt Practices Act (FCPA) and reaped more than $11 million in profits from its misconduct. SEC Findings are, B-MS, operating through its joint venture known as Sino-American Shanghai Squibb Pharmaceuticals, allegedly failed to respond to red flags indicating that sales personnel provided bribes and other benefits to generate sales from HCPs in China, according to the SEC. SEC found that sales representatives provided a variety of benefits to HCPs -- from small food and personal care items to shopping cards, jewelry, sightseeing and cash payments, in exchange for prescription sales. Between mid-2009 and late 2013, B-MS China found "numerous irregularities in travel and entertainment and event documentation, including fake and altered purchase orders, invoices, agendas, and attendance sheets for meetings with HCPs that likely had not occurred. B-MS China also inaccurately recorded the reimbursement of these false claims as legitimate business expenses. One sales representative even went so far as to explain that a former sales representative had offered cash for sales to HCPs at a local hospital and the attitude of the director of the infectious diseases department was extremely clear when took over No money, no prescription.

Bristol-Myers Squibb Company Reports Positive Results from Phase 3 Trial

Bristol-Myers Squibb Company reported positive results from a Phase 3 trial of its cancer drug Opdivo as compared to everolimus in previously treated patients with advanced renal cell carcinoma (RCC). The CheckMate -025 study showed a median overall survival of 25 months for Opdivo-treated patients versus 19.6 months for patients receiving everolimus. The results revealed clinical benefit for Opdivo regardless of level of PD-L1 expression and the safety profile was consistent with previously reported data. The study was stopped in July following an assessment the independent Data Monitoring Committee (DMC), which concluded that CheckMate -025 met its primary endpoint, namely showing improved overall survival in the Opdivo arm. Based on its results, the US Food and Drug Administration (FDA) designated the product as Breakthrough Therapy.

Bristol-Myers Squibb Announces U.S. Food and Drug Administration Regulatory Filing Update for the Opdivo Yervoy Regimen in Patients with Previously Untreated Advanced Melanoma

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review a supplemental Biologics License Application (sBLA) for the Opdivo (nivolumab)+ Yervoy (ipilimumab) regimen to include clinical data from CheckMate -067, a landmark trial in patients with previously untreated advanced melanoma. The FDA also granted Priority Review for this application with a target action date of January 23, 2016. CheckMate -067 is the first Phase 3 trial evaluating the Opdivo + Yervoy regimen or Opdivo monotherapy vs. Yervoy monotherapy in patients with previously untreated advanced melanoma. Results from CheckMate -067 demonstrated superior progression-free survival (PFS) for the Opdivo + Yervoy regimen or Opdivo monotherapy vs. Yervoy monotherapy in previously untreated patients with advanced melanoma, regardless of BRAF status. If approved, this application would expand upon the initial application for the Opdivo+Yervoy regimen, which was based on tumor response rate and safety data from the Phase 2 randomized trial, CheckMate -069. The CheckMate -067 trial that serves as the basis for this submission includes comparative PFS and objective response rate data. Findings from CheckMate -067 provide additional evidence that the combination of two Immuno-Oncology agents, Opdivo and Yervoy, may provide improved outcomes for patients with advanced melanoma, and has the potential to become the basis for how this devastating disease is treated, said Michael Giordano, senior vice president, head of Development, Oncology, Bristol-Myers Squibb. The company saw significant clinical benefit from the Opdivo+Yervoy regimen in these patients, including an increase in the time patients lived without disease progression, and the company look forward to working with the FDA to review this data. The CheckMate -067 trial is ongoing and patients continue to be followed for the co-primary endpoint of overall survival.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $59.39 USD -2.58

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $54.63 USD -2.05
Allergan plc $264.46 USD -14.12
Amgen Inc $140.16 USD -3.64
Eli Lilly & Co $83.86 USD -2.71
Novo Nordisk A/S kr367.00 DKK +0.70
View Industry Companies

Industry Analysis


Industry Average

Valuation BMY Industry Range
Price/Earnings 58.0x
Price/Sales 6.3x
Price/Book 6.8x
Price/Cash Flow 57.7x
TEV/Sales 5.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRISTOL-MYERS SQUIBB CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at